Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- DS-8201 Data Out for Multiple HER2-Expressing Tumors: Daiichi Sankyo
September 13, 2017
- Linzess Filed for Add’l Indication of Chronic Constipation: Astellas
September 12, 2017
- Tumor Regression Seen in 93% of RCC Patients on Lenvima-Keytruda Combo
September 12, 2017
- Lenvima Stalls QOL Lowering in HCC Patients: Eisai
September 12, 2017
- Chugai Sues Nippon Kayaku over Herceptin Patent
September 11, 2017
- Eisai, Ono to Collaborate on Lenvima-Opdivo Combo in HCC
September 11, 2017
- Pres. Fredrickson Leaves AZ Japan Unit after 14 Months in Office
September 11, 2017
- Canalia, Japan’s 1st DPP-4/SGLT-2 Combo, Now Available
September 8, 2017
- Ethical Drug Sales Rise 0.4% in July: Crecon
September 8, 2017
- PI Starts in US for Daiichi Sankyo/Sanford Burnham’s TNAP Inhibitor
September 8, 2017
- Japan PIII for Atopic Dermatitis Drug Nemolizumab to Begin in October: Maruho
September 8, 2017
- Chugai to Expand Range of Drugs on Its Medication Optimization Support Application
September 8, 2017
- Sumitomo Dainippon Licenses Antiemetic to Maruishi in Japan, US
September 7, 2017
- Eisai, Merck to Expand Enrollment of Keytruda Combination Trials with Lenvima/Halaven
September 6, 2017
- Japanese Drug Majors Ratcheting Up Moves in CAR-T Space
September 6, 2017
- Spera Pharma Begins Business Capitalizing on “Takeda’s” Track Record, Aims to Become Japan’s No. 1 CDMO
September 6, 2017
- Takeda in CAR-T Therapy Pact with NCC/Yamaguchi Univ. Spin-Out
September 5, 2017
- Mitsubishi Tanabe to Beef Up Marketing System in Field of Autoimmune Diseases, Plans to Expand Expert Sales Force
September 5, 2017
- Aspen Completes Takeover of 4 Kyowa Kirin Brands
September 4, 2017
- BIKEN-Mitsubishi Tanabe Vaccine JV Now Up and Running
September 4, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…